SCHEMBL353795

SCHEMBL353795

CC(=N)NOC(=O)c1ccc(F)c(C#N)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VNN1 O95497 1/20 0.40
CNR2 P34972 1/20 0.40
GRM4 Q14833 1/20 0.37
S1PR3 Q99500 6/20 0.36
S1PR1 P21453 3/20 0.36
S1PR4 O95977 1/20 0.36
TRPA1 O75762 1/20 0.36
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
GAA P10253 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ABCG2 Q9UNQ0 1/20 0.34
KCNH2 Q12809 1/20 0.34
CES2 O00748 1/20 0.34
CES1 P23141 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA7 P43166 1/20 0.34
XDH P47989 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL366584 0.82 CA1 (0.47) VNN1CNR2GRM4GAASMN1; SMN2
SCHEMBL14012579 0.82 CA1 (0.47) VNN1CNR2GRM4GAASMN1; SMN2
SCHEMBL30961881 0.82 CA1 (0.47) VNN1CNR2GRM4GAASMN1; SMN2
SCHEMBL353794 0.78 RAB9A (0.47) VNN1CNR2SMN1; SMN2ALDH1A1
SCHEMBL353796 0.78 RAB9A (0.47) VNN1CNR2SMN1; SMN2ALDH1A1
SCHEMBL14012595 0.77 CYP11B1 (0.49) VNN1CNR2GRM4S1PR3S1PR1
SCHEMBL586822 0.77 CYP11B1 (0.49) VNN1CNR2GRM4S1PR3S1PR1
SCHEMBL29896891 0.77 CYP11B1 (0.49) VNN1CNR2GRM4S1PR3S1PR1
SCHEMBL6654063 0.75 TRPA1 (0.48) VNN1CNR2GRM4TRPA1GAA
SCHEMBL3085415 0.74 CYP11B2 (0.49) VNN1CNR2GRM4S1PR3S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120015957-A1 PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015957-A1 PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR NPY2R, NPY1R, NPY5R VNN1 2522/4885CNR2 69/4885GRM4 1216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.